Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Mereo Biopharma Group Plc ADR (MREO)

Mereo Biopharma Group Plc ADR (MREO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan Business Wire - Tue Oct 18, 2022

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo”...

MREO : 3.98 (+2.58%)
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five Business Wire - Mon Oct 3, 2022

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo”...

MREO : 3.98 (+2.58%)
Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders Business Wire - Wed Sep 14, 2022

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo”...

MREO : 3.98 (+2.58%)
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire - Tue Jul 5, 2022

LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a...

MREO : 3.98 (+2.58%)
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting Globe Newswire - Thu May 26, 2022

Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2...

MREO : 3.98 (+2.58%)
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency Globe Newswire - Thu May 26, 2022

LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage...

MREO : 3.98 (+2.58%)
Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat Globe Newswire - Fri May 6, 2022

Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET...

MREO : 3.98 (+2.58%)
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat Globe Newswire - Fri May 6, 2022

Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET...

MREO : 3.98 (+2.58%)
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference Globe Newswire - Wed Apr 6, 2022

LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage...

MREO : 3.98 (+2.58%)
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights Globe Newswire - Thu Mar 31, 2022

LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage...

MREO : 3.98 (+2.58%)

Barchart Exclusives

1 Reliable Dividend Stock to Buy at a Discount This July Barchart - Mon Jul 22, 6:30PM CDT
Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot